PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024

Market: Pharmaceuticals and Healthcare

Global, 367 pages report, published by GlobalData

Report ThumbnailSeptember-2015
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024

Summary

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options.

Read More
  • 1.2 List of Figures
  • Figure 1: Accrual of Disability in the Four Subtypes of MS 31
  • Figure 2: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 60
  • Figure 3: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014 62
  • Figure 4: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014 64
  • Figure 5: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 66
  • Figure 6: 10MM, Diagnosed Incide
Read More
  • 1.1 List of Tables
  • Table 1: Common Presenting Symptoms of MS 32
  • Table 2: Factors That Can Affect Prognosis in MS 33
  • Table 3: Risk Factors and Comorbidities for MS 36
  • Table 4: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast 44
  • Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024 59
  • Table 6: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014 61
  • Table 7: 10MM, Diagnosed
Read More
  • 1 Table of Contents
  • 1 Table of Contents 10
  • 1.1 List of Tables 17
  • 1.2 List of Figures 23
  • 2 Introduction 25
  • 2.1 Catalyst 25
  • 2.2 Related Reports 26
  • 3 Disease Overview 27
  • 3.1 Etiology and Pathophysiology 27
  • 3.1.1 Etiology 27
  • 3.1.2 Pathophysiology 28
  • 3.2 Classification 29
  • 3.2.1 Relapse-Remitting Multiple Sclerosis 29
  • 3.2.2 Secondary Progressive Multiple Sclerosis 30
  • 3.2.3 Primary Progressive Multiple Sclerosis 30
  • 3.2.4 Progressive Relapsing Multiple Sclerosis 30
  • 3.3 Symptoms 31
  • 3.4 Prognosis 32
  • 3.5 Q
Read More
  • Multiple Sclerosis Treatment Market Value to Reach $20 Billion by 2024, says GlobalData

    The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 1.5%, according to research and consulting firm GlobalData.

    The company’s latest report* states that this growth, which will occur across the ten major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Canada, Chi
Read More

Please select a license type

Share

Related Products

GlobalDataPharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024Product ThumbnailPharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024, Industry ReportProduct #: 135297
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2021 Global Market Analyst. All Rights Reserved